NOT KNOWN DETAILS ABOUT KEYTRUDA COST

Evaluation Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indicator: Together with chemotherapy, for that cure of Grownup people with domestically recurrent unresectable or metastatic triple-negative breast cancer which have not gained prior chemotherapy for metastatic disease and whose tumours Specific programmed cell death-ligand 1